Great Point Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Great Point Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-80,000	Closed	-$5.23M	–	38
2025 Q3	$5.23M	Sell	80,000 -420,000	-84%	-$20.5M	2.16%	17
2025 Q2	$19.8M	Buy	500,000 +250,000	+100%	+$8.18M	12.84%	1
2025 Q1	$7.54M	Sell	250,000 -255,007	-50%	-$8.35M	4%	11
2024 Q4	$17.7M	Buy	505,007 +250,007	+98%	+$9.34M	8.32%	1
2024 Q3	$10.2M	Sell	255,000 -75,000	-23%	-$3.49M	3.01%	14
2024 Q2	$15.7M	Buy	+330,000	New	+$13.5M	3.01%	14
2021 Q1	–	Sell	-75,000	Closed	-$4.24M	–	32
2020 Q4	$4.24M	Buy	+75,000	New	+$3.74M	0.69%	29
2020 Q1	–	Sell	-65,000	Closed	-$3.93M	–	44
2019 Q4	$3.93M	Sell	65,000 -205,000	-76%	-$12.2M	0.34%	32
2019 Q3	$16.2M	Buy	+270,000	New	+$17.6M	1.49%	22

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Great Point Partners's IONS Position: Q4 2025 in Review

Great Point Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 80,000 shares — an estimated $5.23M sold.

Great Point Partners first reported a position in IONS in Q3 2019 and held it in 9 quarters. The position peaked at $19.8M in Q2 2025. 492 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

Great Point Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Great Point Partners sold 80,000 Ionis Pharmaceuticals shares in Q4 2025, an estimated $5.23M.
Great Point Partners first reported a position in Ionis Pharmaceuticals in Q3 2019 and held it in 9 quarters.
Great Point Partners's Ionis Pharmaceuticals position peaked at $19.8M in Q2 2025.
492 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.